Articles

Optimal glucose, HbA1c, glucose-HbA1c ratio and stress-hyperglycaemia ratio cut-off values for predicting 1-year mortality in diabetic and non-diabetic acute myocardial infarction patients

Stress-induced hyperglycaemia at time of hospital admission has been linked to worse prognosis following acute myocardial infarction (AMI). In addition to glucose, other glucose-related indices, such as HbA1c,...

Authors: Ching-Hui Sia, Mervyn Huan-Hao Chan, Huili Zheng, Junsuk Ko, Andrew Fu-Wah Ho, Jun Chong, David Foo, Ling-Li Foo, Patrick Zhan-Yun Lim, Boon Wah Liew, Ping Chai, Tiong-Cheng Yeo, Huay-Cheem Tan, Terrance Chua, Mark Yan-Yee Chan, Jack Wei Chieh Tan…

Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression

Besides providing reassurance about cardiovascular (CV) safety of newer diabetes drugs, cardiovascular outcome trials (CVOTs) have also shown encouraging benefits on some CV endpoints. The contribution of the ...

Authors: Maria Ida Maiorino, Miriam Longo, Lorenzo Scappaticcio, Giuseppe Bellastella, Paolo Chiodini, Katherine Esposito and Dario Giugliano

A synergistic effect of variability in estimated glomerular filtration rate with chronic kidney disease on all-cause mortality prediction in patients with type 2 diabetes: a retrospective cohort study

The combination of diabetes mellitus (DM) and chronic kidney disease (CKD) is associated with a high risk of mortality. Annual assessment of the estimated glomerular filtration rate (eGFR) is recommended for p...

Authors: Yu-Shan Chang, Yu-Hsuan Li and I-Te Lee

Relationship between skin autofluorescence levels and clinical events in patients with heart failure undergoing cardiac rehabilitation

Advanced glycation end-products, indicated by skin autofluorescence (SAF) levels, could be prognostic predictors of all-cause and cardiovascular mortality in patients with diabetes mellitus (DM) and renal dise...

Authors: Mitsuhiro Kunimoto, Miho Yokoyama, Kazunori Shimada, Tomomi Matsubara, Tatsuro Aikawa, Shohei Ouchi, Kosuke Fukao, Tetsuro Miyazaki, Kei Fujiwara, Abidan Abulimiti, Akio Honzawa, Akie Shimada, Taira Yamamoto, Atsushi Amano, Masakazu Saitoh, Tomoyuki Morisawa…

Visit-to-visit fasting blood glucose variability and lifetime risk of cardiovascular disease: a prospective study

Previous studies suggested an adverse association between higher fasting blood glucose (FBG) variability and cardiovascular disease (CVD). Lifetime risk provides an absolute risk assessment during the remainde...

Authors: Jianing Bi, Lulu Song, Lulin Wang, Mingyang Wu, Shouhua Chen, Youjie Wang, Shouling Wu and Yaohua Tian

Gender difference in the association between TyG index and subclinical atherosclerosis: results from the I-Lan Longitudinal Aging Study

Insulin resistance (IR) is a known risk factor for cardiovascular disease (CVD) in non-diabetic patients through the association of hyperglycemia or associated metabolic factors. The triglyceride glucose (TyG)...

Authors: Ya-Wen Lu, Chun-Chin Chang, Ruey-Hsing Chou, Yi-Lin Tsai, Li-Kuo Liu, Liang-Kung Chen, Po-Hsun Huang and Shing-Jong Lin

GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off

Cardiovascular disease (CVD) remains the leading cause of death in patients with type 2 diabetes (T2D). Older age, prior heart failure (HF) and CV events, peripheral artery disease, and kidney complications ca...

Authors: Dario Giugliano, Lorenzo Scappaticcio, Miriam Longo, Giuseppe Bellastella and Katherine Esposito

Cost-effectiveness evaluation of add-on dapagliflozin for heart failure with reduced ejection fraction from perspective of healthcare systems in Asia–Pacific region

With emerging evidence on the efficacy of adding dapagliflozin to standard care for patients with heart failure with reduced ejection fraction (HFrEF), this study assessed the cost-effectiveness of add-on dapa...

Authors: Chia-Te Liao, Chun-Ting Yang, Han Siong Toh, Wei-Ting Chang, Hung-Yu Chang, Fang-Hsiu Kuo, Mei-Chuan Lee, Yi-Ming Hua, Hsin-Ju Tang, Carol Strong and Huang-Tz Ou

Renoprotective effect of SGLT-2 inhibitors among type 2 diabetes patients with different baseline kidney function: a multi-center study

To assess the effect of sodium glucose cotransporter-2 inhibitors (SGLT-2is) for type 2 diabetes on kidney outcomes stratified by patient baseline estimated glomerular filtration rate (eGFR) levels (i.e., eGFR...

Authors: Fang-Ju Lin, Chi-Chuan Wang, Chien-Ning Hsu, Chen-Yi Yang, Chih-Yuan Wang and Huang-Tz Ou

Estimated glucose disposal rate and risk of stroke and mortality in type 2 diabetes: a nationwide cohort study

Insulin resistance contributes to the development of type 2 diabetes (T2D) and is also a cardiovascular risk factor. The aim of this study was to investigate the potential association between insulin resistanc...

Authors: Alexander Zabala, Vladimer Darsalia, Marcus Lind, Ann-Marie Svensson, Stefan Franzén, Björn Eliasson, Cesare Patrone, Magnus Jonsson and Thomas Nyström

Atherogenic index of plasma is associated with major adverse cardiovascular events in patients with type 2 diabetes mellitus

Previous studies reported the prognostic value of the atherogenic index of plasma (AIP) in the course of atherosclerosis and other cardiovascular diseases (CVDs). Still, the predictive utility of the AIP is un...

Authors: Liyao Fu, Ying Zhou, Jiaxing Sun, Zhaowei Zhu, Zhenhua Xing, Shenghua Zhou, Yongjun Wang and Shi Tai

Impact of empagliflozin on right ventricular parameters and function among patients with type 2 diabetes

Sodium-glucose cotransporter 2 (SGLT2) inhibition reduces cardiovascular events in type 2 diabetes (T2DM) and is associated with a reduction in left ventricular (LV) mass index. However, the impact on right ve...

Authors: Bradley Sarak, Subodh Verma, C. David Mazer, Hwee Teoh, Adrian Quan, Richard E. Gilbert, Shaun G. Goodman, Karan Bami, Otávio R. Coelho-Filho, Vineeta Ahooja, Djeven P. Deva, Vinay Garg, Sumeet Gandhi, Kim A. Connelly and Andrew T. Yan

Empagliflozin protects the heart against ischemia/reperfusion-induced sudden cardiac death

Empagliflozin is a selective sodium–glucose cotransporter 2 (SGLT2) inhibitor used to lower blood sugar in adults with type 2 diabetes. Empagliflozin also exerts cardioprotective effects independent from gluco...

Authors: Zhaoyang Hu, Feng Ju, Lei Du and Geoffrey W. Abbott

The management of type 2 diabetes before, during and after Covid-19 infection: what is the evidence?

Patients with Covid-19 place new challenges on the management of type 2 diabetes, including the questions of whether glucose-lowering therapy should be adjusted during infection and how to manage a return to n...

Authors: Leszek Czupryniak, Dror Dicker, Roger Lehmann, Martin Prázný and Guntram Schernthaner

The association of hepatic steatosis and fibrosis with heart failure and mortality

Nonalcoholic fatty liver disease (NAFLD) is a hepatic manifestation of metabolic disease and independently affects the development of cardiovascular (CV) disease. We investigated whether hepatic steatosis and/...

Authors: Jiyun Park, Gyuri Kim, Hasung Kim, Jungkuk Lee, You-Bin Lee, Sang-Man Jin, Kyu Yeon Hur and Jae Hyeon Kim

Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence

The impressive results of recent clinical trials with glucagon-like peptide-1 receptor agonists (GLP-1Ra) and sodium glucose transporter 2 inhibitors (SGLT-2i) in terms of cardiovascular protection prompted a ...

Authors: Andrea Natali, Lorenzo Nesti, Domenico Tricò and Ele Ferrannini

Diabetes status-related differences in risk factors and mediators of heart failure in the general population: results from the MORGAM/BiomarCaRE consortium

The risk of heart failure among diabetic individuals is high, even under tight glycemic control. The correlates and mediators of heart failure risk in individuals with diabetes need more elucidation in large p...

Authors: Matti A. Vuori, Jaakko Reinikainen, Stefan Söderberg, Ellinor Bergdahl, Pekka Jousilahti, Hugh Tunstall-Pedoe, Tanja Zeller, Dirk Westermann, Susana Sans, Allan Linneberg, Licia Iacoviello, Simona Costanzo, Veikko Salomaa, Stefan Blankenberg, Kari Kuulasmaa and Teemu J. Niiranen

Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND

The REWIND trial demonstrated cardiovascular (CV) benefits to patients with type 2 diabetes and multiple CV risk factors or established CV disease. This exploratory analysis evaluated the degree to which the e...

Authors: Manige Konig, Matthew C. Riddle, Helen M. Colhoun, Kelley R. Branch, Charles M. Atisso, Mark C. Lakshmanan, Reema Mody, Sohini Raha and Hertzel C. Gerstein

Prognostic impact of liver fibrosis and steatosis by transient elastography for cardiovascular and mortality outcomes in individuals with nonalcoholic fatty liver disease and type 2 diabetes: the Rio de Janeiro Cohort Study

Liver stiffness measurement (LSM, which reflects fibrosis) and controlled attenuation parameter (CAP, which reflects steatosis), two parameters derived from hepatic transient elastography (TE), have scarcely b...

Authors: Claudia R. L. Cardoso, Cristiane A. Villela-Nogueira, Nathalie C. Leite and Gil F. Salles

Impact of admission hyperglycemia on short and long-term prognosis in acute myocardial infarction: MINOCA versus MIOCA

The prognostic role of hyperglycemia in patients with myocardial infarction and obstructive coronary arteries (MIOCA) is acknowledged, while data on non-obstructive coronary arteries (MINOCA) are still lacking...

Authors: Pasquale Paolisso, Alberto Foà, Luca Bergamaschi, Francesco Angeli, Michele Fabrizio, Francesco Donati, Sebastiano Toniolo, Chiara Chiti, Andrea Rinaldi, Andrea Stefanizzi, Matteo Armillotta, Angelo Sansonetti, Ilenia Magnani, Gianmarco Iannopollo, Paola Rucci, Gianni Casella…

Hypofibrinolysis in type 2 diabetes and its clinical implications: from mechanisms to pharmacological modulation

A prothrombotic state is a typical feature of type 2 diabetes mellitus (T2DM). Apart from increased platelet reactivity, endothelial dysfunction, hyperfibrinogenemia, and hypofibrinolysis are observed in T2DM....

Authors: Agata Hanna Bryk-Wiązania and Anetta Undas

Comparison of various insulin resistance surrogates on prognostic prediction and stratification following percutaneous coronary intervention in patients with and without type 2 diabetes mellitus

Insulin resistance (IR), evaluation of which is difficult and complex, is closely associated with cardiovascular disease. Recently, various IR surrogates have been proposed and proved to be highly correlated w...

Authors: Qi Zhao, Yu-Jing Cheng, Ying-Kai Xu, Zi-Wei Zhao, Chi Liu, Tie-Nan Sun and Yu-Jie Zhou

GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs

A meta-analysis is presented of cardiovascular outcome trials (CVOTs) comparing glucagon-like peptide-1 receptor agonists (GLP-1RA) versus placebo on cardiorenal outcomes in patients with type 2 diabetes melli...

Authors: Dario Giugliano, Lorenzo Scappaticcio, Miriam Longo, Paola Caruso, Maria Ida Maiorino, Giuseppe Bellastella, Antonio Ceriello, Paolo Chiodini and Katherine Esposito

Association between apolipoprotein B/A1 ratio and coronary plaque vulnerability in patients with atherosclerotic cardiovascular disease: an intravascular optical coherence tomography study

Apolipoprotein (Apo) A1 and Apo B are strongly associated with the risk of atherosclerotic cardiovascular disease (ASCVD). However, the relationship between the Apo B/A1 ratio and the morphology of coronary vu...

Authors: Fuxue Deng, Danni Li, Lei Lei, Qiang Yang, Qing Li, Hongtao Wang, Jie Deng, Qiangsun Zheng and Wei Jiang

Body weight changes in patients with type 2 diabetes and a recent acute coronary syndrome: an analysis from the EXAMINE trial

Patients with type 2 diabetes (T2D) may experience frequent body weight changes over time. The prognostic impact of these weight changes (gains or losses) requires further study.

Authors: João Pedro Ferreira, Patrick Rossignol, George Bakris, Cyrus Mehta, William B. White and Faiez Zannad

Effects of canagliflozin on NT-proBNP stratified by left ventricular diastolic function in patients with type 2 diabetes and chronic heart failure: a sub analysis of the CANDLE trial

Identification of the effective subtypes of treatment for heart failure (HF) is an essential topic for optimizing treatment of the disorder. We hypothesized that the beneficial effect of SGLT2 inhibitors (SGLT...

Authors: Kenya Kusunose, Takumi Imai, Atsushi Tanaka, Kaoru Dohi, Kazuki Shiina, Takahisa Yamada, Keisuke Kida, Kazuo Eguchi, Hiroki Teragawa, Yasuchika Takeishi, Nobuyuki Ohte, Hirotsugu Yamada, Masataka Sata and Koichi Node

Effect of diabetes mellitus on the development of left ventricular contractile dysfunction in women with heart failure and preserved ejection fraction

Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous syndrome with sex-specific pathophysiology. Estrogen deficiency is believed to be responsible for the development of HFpEF in women. Ho...

Authors: Ke Shi, Meng-Xi Yang, Shan Huang, Wei-Feng Yan, Wen-Lei Qian, Yuan Li, Ying-Kun Guo and Zhi-Gang Yang

Correction to: Association between carotid plaque vulnerability and high mobility group box‑1 serum levels in a diabetic population

Authors: Federico Biscetti, Giovanni Tinelli, Maria Margherita Rando, Elisabetta Nardella, Andrea Leonardo Cecchini, Flavia Angelini, Giuseppe Straface, Marco Filipponi, Vincenzo Arena, Dario Pitocco, Antonio Gasbarrini, Massimo Massetti and Andrea Flex

Positive association between the ratio of triglycerides to high-density lipoprotein cholesterol and diabetes incidence in Korean adults

Insulin resistance is associated with the incidence of diabetes and cardiovascular diseases such as myocardial infarction. The ratio of triglycerides (TG) to high-density lipoprotein cholesterol (HDL-C) (TG/HD...

Authors: Joungyoun Kim, Sang-Jun Shin, Ye-Seul Kim and Hee-Taik Kang

Basement membrane proteins in various arterial beds from individuals with and without type 2 diabetes mellitus: a proteome study

Basement membrane (BM) accumulation is a hallmark of micro-vessel disease in diabetes mellitus (DM). We previously reported marked upregulation of BM components in internal thoracic arteries (ITAs) from type 2...

Authors: Lasse Bach Steffensen, Xenia Emilie Sinding Iversen, Rasmus Søgaard Hansen, Pia Søndergaard Jensen, Anne-Sofie Faarvang Thorsen, Jes Sanddal Lindholt, Lars Peter Schødt Riber, Hans Christian Beck and Lars Melholt Rasmussen

External applicability of SGLT2 inhibitor cardiovascular outcome trials to patients with type 2 diabetes and cardiovascular disease

Recent treatment guidelines support the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in patients with type 2 diabetes and cardiovascular disease based on the results of cardiovascular outcome tria...

Authors: Lisanne C. A. Smidt, Frank L. J. Visseren, Wendela L. de Ranitz-Greven, Hendrik M. Nathoe, L. Jaap Kappelle, Gert J. de Borst, Harold W. de Valk and Jan Westerink

Impact of insulin therapy on the mortality of acute heart failure patients with diabetes mellitus

Patients with diabetes mellitus (DM) have a higher prevalence of heart failure (HF) than those without it. Approximately 40 % of HF patients have DM and they tend to have poorer outcomes than those without DM....

Authors: Se Yong Jang, Jieun Jang, Dong Heon Yang, Hyun-Jai Cho, Soo Lim, Eun-Seok Jeon, Sang Eun Lee, Jae-Joong Kim, Seok-Min Kang, Sang Hong Baek, Myeong-Chan Cho, Dong-Ju Choi, Byung-Su Yoo, Kye Hun Kim, Sue K. Park and Hae-Young Lee

Effect of anti-diabetic drugs in dialysis patients with diabetes: a nationwide retrospective cohort study

Type 2 diabetes mellitus is common in patients undergoing dialysis. However, the association between anti-diabetic drug use and survival outcomes is rarely discussed. We aimed to investigate whether continued ...

Authors: Shih-Hsiang Ou, Hsin-Yu Chen, Nai-Wen Fang, Chun-Hao Yin, Chien-Liang Chen and Jin-Shuen Chen

Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine

Type 2 diabetes causes cardio-renal complications and is treated with different combination therapies. The renal hemodynamics profile of such combination therapies has not been evaluated in detail.

Authors: Christian Ott, Susanne Jung, Manuel Korn, Dennis Kannenkeril, Agnes Bosch, Julie Kolwelter, Kristina Striepe, Peter Bramlage, Mario Schiffer and Roland E. Schmieder

Correction to: Sodium–glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta‑analysis

Authors: Hang-Long Li, Gregory Y. H. Lip, Qi Feng, Yue Fei, Yi-Kei Tse, Mei-zhen Wu, Qing-wen Ren, Hung-Fat Tse, Bernard-M. Y. Cheung and Kai-Hang Yiu

Efficacy and safety of direct-acting oral anticoagulants compared to vitamin K antagonists in COVID-19 outpatients with cardiometabolic diseases

It remains uncertain if prior use of oral anticoagulants (OACs) in COVID-19 outpatients with multimorbidity impacts prognosis, especially if cardiometabolic diseases are present. Clinical outcomes 30-days afte...

Authors: José Miguel Rivera-Caravaca, Stephanie L. Harrison, Benjamin J. R. Buckley, Elnara Fazio-Eynullayeva, Paula Underhill, Francisco Marín and Gregory Y. H. Lip

Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents

Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of a deterioration in heart failure (HF) and mortality in patients with a broad range of cardiovascular risks. Recent guidelines recommend cons...

Authors: Atsushi Tanaka, Shigeru Toyoda, Takumi Imai, Kazuki Shiina, Hirofumi Tomiyama, Yasushi Matsuzawa, Takahiro Okumura, Yumiko Kanzaki, Katsuya Onishi, Arihiro Kiyosue, Masami Nishino, Yasushi Sakata and Koichi Node

Impact of prior cerebrovascular disease and glucose status on incident cerebrovascular disease in Japanese

Although both a history of cerebrovascular disease (CVD) and glucose abnormality are risk factors for CVD, few large studies have examined their association with subsequent CVD in the same cohort. Thus, we com...

Authors: Momoko Oe, Kazuya Fujihara, Mayuko Harada-Yamada, Taeko Osawa, Masaru Kitazawa, Yasuhiro Matsubayashi, Takaaki Sato, Yuta Yaguchi, Midori Iwanaga, Hiroyasu Seida, Takaho Yamada and Hirohito Sone

Variability in body weight and the risk of cardiovascular complications in type 2 diabetes: results from the Swedish National Diabetes Register

There is a high incidence of cardiovascular disease in diabetes. Weight variability has been reported as independent risk factor for cardiovascular disease in the general population and preliminarily also in p...

Authors: Antonio Ceriello, Giuseppe Lucisano, Francesco Prattichizzo, Björn Eliasson, Stefan Franzén, Ann-Marie Svensson and Antonio Nicolucci

Persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin

Severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2)-induced infection, the cause of coronavirus disease 2019 (COVID-19), is characterized by acute clinical pathologies, including various coagulopathie...

Authors: Etheresia Pretorius, Mare Vlok, Chantelle Venter, Johannes A. Bezuidenhout, Gert Jacobus Laubscher, Janami Steenkamp and Douglas B. Kell

Prognostic value of subclinical myocardial necrosis using high-sensitivity cardiac troponin T in patients with prediabetes

Risk stratification of patients with prediabetes is an unmet clinical need. Here, we examine the utility of subclinical myocardial necrosis assessed by high-sensitivity cardiac troponin T (hs-cTnT) in predicti...

Authors: Marco Witkowski, Yuping Wu, Stanley L. Hazen and W. H. Wilson Tang

Autonomic nervous system activity changes in patients with hypertension and overweight: role and therapeutic implications

The incidence and prevalence of hypertension is increasing worldwide, with approximately 1.13 billion of people currently affected by the disease, often in association with other diseases such as diabetes mell...

Authors: Paul Valensi

Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence

Randomized controlled trials showed that sodium/glucose cotransporter-2 inhibitors (SGLT2i) protect the heart and kidney in an array of populations with type 2 diabetes (T2D) and increased cardiorenal risk. Ho...

Authors: Meir Schechter, Cheli Melzer-Cohen, Aliza Rozenberg, Ilan Yanuv, Gabriel Chodick, Avraham Karasik, Mikhail Kosiborod and Ofri Mosenzon

Association of sex-specific differences in lipoprotein(a) concentrations with cardiovascular mortality in individuals with type 2 diabetes mellitus

Compared to individuals without type 2 diabetes mellitus, the relative increase in cardiovascular mortality is much higher in women than in men in individuals with type 2 diabetes mellitus.

Authors: Marcello Ricardo Paulista Markus, Till Ittermann, Sabine Schipf, Martin Bahls, Matthias Nauck, Henry Völzke, Raul Dias Santos, Annette Peters, Tanja Zeller, Stephan Burkhard Felix, Ramachandran S. Vasan, Barbara Thorand, Elisabeth Steinhagen-Thiessen and Marcus Dörr

The risk of consequent nephropathy following initial weight loss in diabetic patients treated with sodium glucose cotransporter 2 inhibitors

There is a controversy over the association between obesity and the risk of renal events in patients with type 2 diabetes mellitus (T2DM). Furthermore, whether body weight (BW) loss following sodium glucose co...

Authors: Yi-Hsin Chan, Shao-Wei Chen, Tze-Fan Chao, Yi-Wei Kao, Chien-Ying Huang and Pao-Hsien Chu

Plasma nesfatin-1 and DDP-4 levels in patients with coronary artery disease: Kozani study

Nesfatin-1, a novel adipokine and dipeptidyl peptidase-4 (DPP4), a mam malian serine protease, are potent factors of atherosclerosis. In the present cross-sectional study, we investigated whether the plasma ne...

Authors: Nikolaos P. E. Kadoglou, Emmanouil Korakas, Stylianos Lampropoulos, Eirini Maratou, George Kassimis, Nikolaos Patsourakos, Panagiotis Plotas, Paraskevi Moutsatsou and Vaia Lambadiari

Cardiac adipose tissue volume and IL-6 level at admission are complementary predictors of severity and short-term mortality in COVID-19 diabetic patients

COVID-19 diabetic adults are at increased risk of severe forms irrespective of obesity. In patients with type-II diabetes, fat distribution is characterized by visceral and ectopic adipose tissues expansion, r...

Authors: Franck Phan, Samia Boussouar, Olivier Lucidarme, Mohamed Zarai, Joe-Elie Salem, Nadjia Kachenoura, Khaoula Bouazizi, Etienne Charpentier, Yasmine Niati, Hasnae Bekkaoui, Zahir Amoura, Alexis Mathian, Olivier Benveniste, Patrice Cacoub, Yves Allenbach, David Saadoun…

High-risk coronary artery plaque in asymptomatic patients with type 2 diabetes: clinical risk factors and coronary artery calcium score

High-risk coronary artery plaque (HRP) is associated with increased risk of acute coronary syndrome.

Authors: Laurits Juhl Heinsen, Gokulan Pararajasingam, Thomas Rueskov Andersen, Søren Auscher, Hussam Mahmoud Sheta, Helle Precht, Jess Lambrechtsen and Kenneth Egstrup

Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trial

Patients with diabetes mellitus (DM) are at increased risk of developing heart failure (HF). The “Heart OMics in AGEing” (HOMAGE) trial suggested that spironolactone had beneficial effect on fibrosis and cardi...

Authors: Job A. J. Verdonschot, João Pedro Ferreira, Pierpaolo Pellicori, Hans-Peter Brunner-La Rocca, Andrew L. Clark, Franco Cosmi, Joe Cuthbert, Nicolas Girerd, Beatrice Mariottoni, Johannes Petutschnigg, Patrick Rossignol, John G. F. Cleland, Faiez Zannad and Stephane R. B. Heymans

Role of obesity and hypertension in the incidence of atrial fibrillation, ischaemic heart disease and heart failure in patients with diabetes

In a cohort study performed using primary care databases in a General Practitioners Network, Groenewegen et al. report a clear association between diabetes and incidence of the major chronic progressive heart ...

Authors: Lucia La Sala and Antonio E. Pontiroli